Who are Bolt Biotherapeutics's investors?

Bolt Biotherapeutics's investors include Pfizer Venture Investments, RA Capital, Vivo Capital, Sofinnova Ventures.

Bolt Biotherapeutics

NASDAQ: BOLT

4 known investors

Bolt Biotherapeutics develops cancer immunotherapies that use the innate immune system to help the body recognize and eliminate tumor cells. Its Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform combines tumor-targeting antibodies with immune-stimulating payloads, with a lead candidate BDC-4182 targeting claudin 18.2 in Phase 1 trials for gastric and related cancers.</parameter> <parameter name="sector_codes">["biotech", "medtech", "healthtech"]

Investors · 4

Pfizer Venture Investments$5M – $20M

RA CapitalBoston

Vivo CapitalPalo Alto · $10M – $50M

Sofinnova VenturesreportedMenlo Park · $100K – $15M

Competitors · 2

by search overlap

Northwest Biotherapeutics20 shared keywordsNorthwest Biotherapeutics is a clinical-stage biotechnology company developing personalized cancer vaccines, marketed under the DCVax platform, that use activated dendritic cells to treat a range of solid tumor cancers. Its product lines include DCVax-L, DCVax-Direct, and DCVax-Prostate.

Bioworld19 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Bolt Biotherapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

BioCentury - Bolt raises $54M series Bbiocentury.com · Feb 2019

Bolt Biotherapeutics Raises $54M in Series B Financing - FinSMEsfinsmes.com · Feb 2019

Frequently asked questions

What does Bolt Biotherapeutics do?: Bolt Biotherapeutics develops cancer immunotherapies that use the innate immune system to help the body recognize and eliminate tumor cells. Its Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform combines tumor-targeting antibodies with immune-stimulating payloads, with a lead candidate BDC-4182 targeting claudin 18.2 in Phase 1 trials for gastric and related cancers.</parameter> <parameter name="sector_codes">["biotech", "medtech", "healthtech"]
Who are Bolt Biotherapeutics's investors?: Bolt Biotherapeutics's investors include Pfizer Venture Investments, RA Capital, Vivo Capital, Sofinnova Ventures.